Accès ouvert déclaré
2022
article
Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis
Ryan Malcolm Hum, Pauline Ho, Nisha Nair, Meghna Jani, John D. Isaacs, Anthony G. Wilson, Kimme L Hyrich, Darren Plant, Anne Barton, Hill Gaston, D. Mulherin, T Price, Thomas Sheeran, V Chalam, Sivasubramanian Baskar, Paul Emery, Ann W Morgan, MH Buch, Sarah Bingham, Séamus O’Reilly, Louisa J Badcock, Marian Regan, T. Ding, Chris Deighton, Gregory D. Summers, N. Raj, Randall M. Stevens, Nicola Williams, Philip Platt, Douglas G. Walker, Lesley Kay, Bridget Griffiths, Wan‐Fai Ng, Paul Peterson, Alice Lorenzi, Helen Foster, Mark Friswell, Ben Thompson, Michael S. Lee, I D Griffiths, Andrew Hassell, Piers Dawes, Christopher G. Dowson, Sanjeet Kamath, Jon Packham, M F Shadforth, Ann Brownfield, Ruth Williams, Chetan Mukhtyar, Beverley Harrison, Neil Snowden, Saima Naz, Joanna Ledingham, R G Hull, F McCrae, Alexander Thomas, Sang-Yeon Min, Ramon Z. Shaban, Edwin Wong, C. Kelly, C. Heycock, J. Hamilton, V. Saravanan, G. M. Wilson, Daniel V. Bax, Lisa Dunkley, Mohamed Akil, Rachel Tattersall, Rachael Kilding, Simon Till, J. Boulton, T Tait, Marwan Bukhari, Jim Halsey, L Ottewell, Christopher D. Buckley, Deva Situnayake, DOUGLAS G. CARRUTHERS, K A Grindulis, F Khatack, Srinivasa Elamanchi, Karim Raza, Andrew Filer, R. W. Jubb, Robert S. Abernathy, Michael Plant, Sanjay Pathare, Fiona Clarke, SP Tuck, J N Fordham, Alok Kumar Paul, M Bridges, Alan J. Hakim, Derek O’Reilly, Vivek Rajagopal, Shweta Bhagat, Christopher J Edwards, P. Prouse, R Moitra, D Shawe, Andrew Bamji, P S Klimiuk, A P Bowden, William Mitchell, Ian N Bruce, Rachel Gorodkin, William G Dixon, Abhishek Rai, George D. Kitas, Nicola Erb, Rainer Klocke, Karen Douglas, A Pace, Ravinder Sandhu, Andrew Whallett, Fraser Birrell, Maggie Allen, К. Ray Chaudhuri, C Chattopadhyay, J F McHale, A Jones, Anil K. Gupta, Ira Pande, Ian Gaywood, Peter Lanyon, P A Courtney, Michael Doherty, Hector Chinoy, Terence W O’Neill, Ariane L. Herrick, R G Cooper, R C Bucknall, Christopher Marguerie, S. Rigby, Nathan Dunn, S Green, Aliya Al-Ansari, S Webber, Neil Hopkinson, Colum Dunne, Brian Quilty, B Szebenyi, Manfred S. Green, Mark Quinn, A. H. Isdale, Andrew K. Brown, Benazir Saleem, A Samanta, P Sheldon, W Hassan, James N. Francis, Alison Kinder, R Neame, Arumugam Moorthy, W Al-Allaf, A. J. Taggart, Kevin Fairburn, Frank McKenna, Michael Green, Andrew Gough, Catherine Lawson, Margaret Piper, Eleanor Korendowych, T Jenkinson, Raj Sengupta, A K Bhalla, Neil McHugh, Dale S. Bond, Raashid Luqmani, B Bowness, Paul Wordsworth, Jean‐Louis David, W. P. Smith, Devesh Mewar, E J Tunn, K Nelson, Tom D. Kennedy, Jane Nixon, Anthony D. Woolf, M Davis, David Hutchinson, Alison Endean, David Coady, D. Wright, Craig Morley, Graham Raftery, C. Bracewell, Louise Kidd, Ismail Abbas, Charlotte Filer, G Kallarackal
8Citations signalées, ce qui n’est pas une note de qualité
10Institutions déclarées
2Pays d’affiliation déclarés
Rattachement africain : gb, ie.
Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVES: Interventions aimed at increasing TNF-α inhibitor serum drug levels (SDLs) may improve treatment response; however, previous studies suggesting SDL cut-offs have not accounted for treatment adherence. The aim of this study was to establish the relationship between adalimumab/certolizumab SDLs and EULAR good vs non-/moderate response and to define SDL cut-offs associated with good response in fully adherent patients. METHODS: In a prospective observational study, 475 patients with RA were treated with certolizumab (n = 192) or adalimumab (n = 283). At baseline and 3, 6 and 12 months, patients had 28-joint DAS, self-reported treatment adherence and SDLs measured. Fully adherent patients were analysed as a subgroup. Follow-up data at 3, 6 and 12 months were analysed separately. Median SDLs were compared in good vs non-/moderate response patients and receiver operating characteristics (ROC) curves were used to establish cut-off SDLs. RESULTS: Fully adherent good responders had significantly higher median adalimumab/certolizumab SDLs compared with non-/moderate responders (P = 0.04 and P = 0.0005, respectively). ROC analysis reported 3 month non-trough adalimumab SDLs discriminated good vs non-/moderate response with an area under the curve (AUC) of 0.63 (95% CI 0.52, 0.75), with a cut-off of 7.5 mg/l being 39.1% specific and 80.9% sensitive. Similarly, 3 month non-trough certolizumab SDLs discriminated good vs non-/moderate response with an AUC of 0.65 (95% CI 0.51, 0.78), with a cut-off of 26.0 mg/l being 43.9% specific and 77.8% sensitive. CONCLUSION: In fully adherent patients, higher SDLs are detected in good responders, suggesting that interventions to improve SDLs, such as encouraging adherence, could improve treatment response. The 3 month non-trough SDL cut-offs of 7.5 mg/l for adalimumab and 26.0 mg/l for certolizumab may be useful in clinical practice.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis
- Date Crossref
- 03/10/2022
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.
Les sujets associés
Rheumatoid Arthritis Research and TherapiesSpondyloarthritis Studies and TreatmentsBiosimilars and Bioanalytical Methods